IP Library › Assignment 064748/0552
Patent Assignment
Reel/Frame 064748/0552

Security Interest

Recorded: 2023-08-29 Pages: 27
Assignor
BLUEPRINT MEDICINES CORPORATION
Executed: 2022-06-30
Assignee
TAO TALENTS, LLC
2100 MCKINNEY AVE, SUITE 1500, DALLAS, TEXAS, 75201
Covered Properties (79)
MAP4K1 Inhibitors
Application: 17/968,439 →
Publication: US 2023/0140954
MAP4K1 Inhibitors
Application: 17/864,106 →
Publication: US 2023/0112729
GSK3a INHIBITORS AND METHODS OF USE THEREOF
Application: 63/465,428 →
Compositions Useful for Treating Disorders Related to Kit
Application: 17/983,747 →
Publication: US 2023/0129944
Dosing Regimens of (S)-1-(4-Fluorophenyl)-1-(2-(4-(6-(1-Methyl-1H-Pyrazol-4-Yl)Pyrrolo[2,1-F][1,2,4]Triazin-4-Yl)Piperazin-1-Yl)Pyrimidin-5-Yl)Ethan-1-Amine for Treatment of Indolent Systemic Mastocytosis
Application: 18/077,431 →
Publication: US 2023/0124801
Crystalline Forms of (S)-1-(4-Fluorophenyl)-1-(2-(4-(6-(1-Methyl-1H-Pyrazol-4-Yl)Pyrrolo[2,1-F][1,2,4]Triazin-4-Yl)Piperazinyl)-Pyrimidin-5-Yl)Ethan-1-Amine and Methods of Making
Application: 18/077,466 →
Publication: US 2023/0271971
Methods for Treating Systemic Mastocytosis and Gastrointestinal Stromal Tumors
Application: 18/199,118 →
Publication: US 2024/0382493
Egfr Inhibitors
Application: 17/883,006 →
Publication: US 2023/0026209
Compositions and Methods for Treating Kit- and Pdgfra-Mediated Diseases
Application: 18/031,714 →
Publication: US 2023/0391780
Compositions and Methods for Treating Kit- and Pdgfra-Mediated Diseases
Application: 18/031,688 →
Publication: US 2024/0010652
Egfr Inhibitors
Application: 17/883,743 →
Publication: US 2023/0019732
Pyrimidine Compounds, Compositions, and Medicinal Applications Thereof
Application: 18/033,954 →
Publication: US 2024/0051945
Pyrimidine Compounds, Compositions, and Medicinal Applications Thereof
Application: 18/033,931 →
Publication: US 2023/0416232
Egfr Inhibitors for Treatment of Cancer
Application: 63/417,489 →
Egfr Inhibitors for Treatment of Cancer
Application: 63/421,516 →
Egfr Inhibitors
Application: 63/406,386 →
Wild Type Kit Inhibitors
Application: 63/428,804 →
Wild Type Kit Inhibitors
Application: 63/445,787 →
Egfr Inhibitors for Treatment of Cancer
Application: 63/421,523 →
Egfr Inhibitors for Treatment of Cancer
Application: 63/440,804 →
Egfr Inhibitors for Treatment of Cancer
Application: 63/468,875 →
Inhibitors of Activin Receptor-Like Kinase
Application: 18/137,228 →
Publication: US 2024/0158398
Method of Preparing Pralsetinib
Application: 18/255,402 →
Publication: US 2024/0059672
Pralsetinib Pharmaceutical Compositions
Application: 18/000,166 →
Publication: US 2023/0203009
Solid Forms of Pralsetinib
Application: 18/000,168 →
Publication: US 2023/0295121
CDK2 Inhibitors
Application: 18/166,178 →
Publication: US 2023/0322791
CDK2 Inhibitors
Application: 63/478,404 →
CDK2 Inhibitors
Application: 63/478,407 →
CDK2 Inhibitors
Application: 63/496,146 →
Solid Forms of CDK2 Inhibitor
Application: 63/478,413 →
CDK2 Inhibitors
Application: 63/478,410 →
CDK2 Inhibitors for Treatment of Cancer
Application: 63/484,383 →
CDK2 Inhibitors for Treatment of Cancer
Application: 63/505,507 →
Substituted Pyrimidine Compounds, Compositions and Medicinal Applications Thereof
Application: 14/913,508 →
Publication: US 2016/0207905
MAP4K1 Inhibitors
MAP4K1 Inhibitors
Kit Inhibitors
Compositions Useful for Treating Disorders Related to Kit
Crystalline Forms of (S)-1-(4-Fluorophenyl)-1-(2-(4-(6-(1-Methyl-1H-Pyrazol-4-Yl)Pyrrolo[2,1-F][1,2,4]Triazin-4-Yl)Piperazinyl)-Pyrimidin-5-Yl)Ethan-1-Amine and Methods of Making
Kit Mutations
Compositions and Methods for Treating Kit- and Pdgfra-Mediated Diseases
Treatment of Eosinophilic Disorder
Treatment of Mast Cell Diseases and Eosinophilic Disorders
Compositions Useful for Treating Disorders Related to Kit
Compositions Useful for Treating Disorders Related to Kit
Compositions Useful for Treating Disorders Related to Kit
Compositions Useful for Treating Disorders Related to Kit and Pdfgr
Compounds and Compositions Useful for Treating Disorders Related to Kit and Pdgfr
Egfr Inhibitors
Egfr Inhibitors
Fused Pyrimidine Compounds, Compositions and Medicinal Applications Thereof
Egfr Inhibitors for Treatment of Cancer
Salt and Crystal Forms of an Epidermal Growth Factor Receptor Inhibitor
Inhibitors of Activin Receptor-Like Kinase
Inhibitors of Activin Receptor-Like Kinase
Salt and Crystal Forms of an Activin Receptor-Like Kinase Inhibitor
Process for Preparing an Activin Receptor-Like Kinase Inhibitor
Ret Inhibitor
Treatment of Egfr-Mutant Cancer
Inhibitors of Ret
CDK2 Inhibitors and Methods of Making and Using Same
CDK2 Inhibitors and Methods of Making and Using Same
Inhibitors of the Fibroblast Growth Factor Receptor
Inhibitors of the Fibroblast Growth Factor Receptor
Inhibitors of the Fibroblast Growth Factor Receptor
Inhibitors of Ret
Inhibitors of Ret
Compounds Useful for Treating Disorders Related to Ret
Compounds Useful for Treating Disorders Related to Ret
PIK3C2G Fusions
NTRK2 Fusions
PIK3CA Fusions
Met Fusions
RAF1 Fusions
PKN1 Fusions
Tert Fusions
Prkc Fusions
Fgr Fusions
Prkacb Fusions
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Sep 8, 2022
From: BROOIJMANS, NATASJA; BRUBAKER, JASON D.; CAMPBELL, JOHN EMMERSON; DE SAVI, CHRISTOPHER
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 061025/0178 →
Assignment of Assignor's Interest Sep 8, 2022
From: AHMAD, OMAR; CAMPBELL, JOHN EMMERSON; DINEEN, THOMAS A.; ENO, MEREDITH SUZANNE
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 061025/0537 →
Assignment of Assignor's Interest Oct 28, 2022
From: FERNANDO, DILINIE PRASADHINI
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 061578/0185 →
Assignment of Assignor's Interest Nov 9, 2022
From: HODOUS, BRIAN L.; KIM, JOSEPH L.; WILSON, KEVIN J.; WILSON, DOUGLAS
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 061711/0030 →
Assignment of Assignor's Interest Dec 16, 2022
From: BRUBAKER, JASON D.; MIDUTURU, CHANDRASEKHAR V.; BURKE, MICHAEL J.; DINEEN, THOMAS A.
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 062150/0587 →
Assignment of Assignor's Interest Feb 28, 2023
From: MAR, BRENTON
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 062822/0823 →
Assignment of Assignor's Interest Feb 28, 2023
From: HAIDLE, ANDREW MARC
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 062834/0050 →
Assignment of Assignor's Interest Feb 28, 2023
From: HAIDLE, ANDREW MARC
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 062834/0078 →
Assignment of Assignor's Interest Feb 28, 2023
From: CONTI, CHIARA; ZALUTSKAYA, ALENA
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 062823/0013 →
Assignment of Assignor's Interest Mar 1, 2023
From: MIDUTURU, CHANDRASEKHAR V.
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 062838/0202 →
Assignment of Assignor's Interest Mar 17, 2023
From: BRUBAKER, JASON D; MIDUTURU, CHANDRASEKHAR V.; BURKE, MICHAEL J; DINEEN, THOMAS A
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 063116/0877 →
Assignment of Assignor's Interest Mar 21, 2023
From: CONTI, CHIARA; ZALUTSKAYA, ALENA
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 063045/0577 →
Assignment of Assignor's Interest Apr 4, 2023
From: BRUBAKER, JASON D.; CLOSE, JOSHUA T.; DINEEN, THOMAS A.; MIDUTURU, CHANDRASEKHAR V.
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 063212/0922 →
Assignment of Assignor's Interest Apr 13, 2023
From: DINEEN, THOMAS A.
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 063314/0771 →
Assignment of Assignor's Interest Apr 13, 2023
From: LYDON, NICHOLAS
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 063314/0744 →
Assignment of Assignor's Interest May 30, 2023
From: ANKROM, WENDY; SURAM, ANITHA
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 063799/0290 →
Assignment of Assignor's Interest Jul 12, 2023
From: WAETZIG, JOSHUA D.; WILKIE, GORDON
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 064226/0359 →
Assignment of Assignor's Interest Oct 30, 2023
From: MAR, BRENTON; PANDY, ANJALI; PEARSON, PAUL; ZALUTSKAYA, ALENA
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 065391/0672 →
Assignment of Assignor's Interest Oct 30, 2023
From: MAR, BRENTON; PANDY, ANJALI; PEARSON, PAUL; ZALUTSKAYA, ALENA
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 065391/0648 →
Assignment of Assignor's Interest Oct 30, 2023
From: ANKROM, WENDY; MAR, BRENTON; PANDY, ANJALI; PEARSON, PAUL
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 065391/0823 →
Assignment of Assignor's Interest Nov 10, 2023
From: BRUBAKER, JASON D.; BURKE, MICHAEL; DINEEN, THOMAS A.; ENO, MEREDITH SUZANNE
To: BLUEPRIINT MEDICINES CORPORATION
Reel/Frame 065526/0882 →
Assignment of Assignor's Interest Nov 15, 2023
From: BRUBAKER, JASON D.; DAI, YINGHUI; DINEEN, THOMAS A.; DU, GUANGYAN
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 065570/0598 →
Assignment of Assignor's Interest Dec 1, 2023
From: BROOIJMANS, NATASJA; BRUBAKER, JASON D.; FLEMING, PAUL E.; HODOUS, BRIAN LEWIS
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 065735/0533 →
Assignment of Assignor's Interest Jan 17, 2024
From: MAR, BRENTON
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 066149/0234 →
Assignment of Assignor's Interest Feb 1, 2024
From: HALLUR, GURULINGAPPA; MADHYASTHA, NAVEENA; STEPHEN, MICHAEL RAJESH
To: JUBILANT BIOSYS LIMITED
Reel/Frame 066333/0085 →